Chiusura precedente | 1,6500 |
Aperto | 1,6200 |
Denaro | 1,6300 x 3100 |
Lettera | 1,6400 x 34100 |
Min-Max giorno | 1,6000 - 1,6900 |
Intervallo di 52 settimane | 1,1100 - 5,9700 |
Volume | |
Media Volume | 3.779.358 |
Capitalizzazione | 657,427M |
Beta (5 anni mensile) | 1,85 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,0560 |
Prossima data utili | 03 ago 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 3,57 |
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA (icosapent ethyl) in specific patient subgroups at increased risk of a cardiovascular (CV) event from the landmark REDUCE-IT® cardiovascular outcomes trial have been accepted for presentation at the European Society of Cardiology (ESC) Congress, both online and onsite in Barcelona, August 26-29, 2022.
Company Received Final Positive Reimbursement Decision for VAZKEPA® by UK’s NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Initiated Comprehensive Cost Reduction Plan in June to Address Market Dynamics in the U.S. with Expected Savings of $100 Million Over 12 Months* Plans On Track for Regulatory Filings for Approval of VASCEPA® (icosapent ethyl) in Several Additional Countries in 2022 Company to Host Conference Ca
DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s second quarter 2022 financial results on Wednesday, August 3rd, 2022 at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s second quarter 2022 financial results in the pre-market hours. Conference Call and Webcast Information